After hours: 4:00PM EDT
|Bid||19.29 x 1400|
|Ask||19.31 x 900|
|Day's Range||19.07 - 19.57|
|52 Week Range||17.67 - 25.48|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||11.79|
|Earnings Date||Oct 3, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.67|
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing agreement by Premier, Inc.
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2020 before the market open on Thursday, October 3, 2019.
How far off is AngioDynamics, Inc. (NASDAQ:ANGO) from its intrinsic value? Using the most recent financial data, we'll...
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics Inc (ANGO) files its latest 10-K with SEC for the fiscal year ended on May 31, 2019. AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Continue reading...
Sales increased by $15 million last year to $359.5 million, with about half of that growth coming from international customers.
AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
Jim Clemmer has been the CEO of AngioDynamics, Inc. (NASDAQ:ANGO) since 2016. First, this article will compare CEO...
NEW YORK, NY / ACCESSWIRE / July 10, 2019 / AngioDynamics, Inc. (NASDAQ: ANGO ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 10, 2019 at 8:00 AM Eastern ...
AngioDynamics (NASDAQ: ANGO ) unveils its next round of earnings this Wednesday, July 10. Get prepared with Benzinga's ultimate preview for AngioDynamics's Q4 earnings. Earnings and Revenue Wall Street ...
Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week. Activity was light, although news on clinical trial readouts ...
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CEO Jim Clemmer was hired in 2016 to turn around AngioDynamics. The plan: Sell off some legacy products and invest in next-generation oncology technology to eventually make the company even bigger.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019.
AngioDynamics will lease the 9th floor of the 10-story Monument Square building in a plan that will bring 125 employees into downtown Glens Falls. The medical device maker is taking approximately 15,000 square feet of office space to accommodate personnel, most of whom previously worked at 10 Glens Falls Technical Park, the former Navilyst building that was sold to Medline Industries last week for $5.75 million. The move is part of AngioDynamics' strategy to improve communication, restructure its manufacturing operations and build a stronger corporate culture, said Dave Helsel, senior vice president of global operations, research and development.
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference at 1:50 p.m.